FAKTOR-OPTIONSSCHEIN - ASTRAZENECA | Market Closed - Börse Stuttgart 10:31:50 2024-06-14 EDT | ||
| 17.5 EUR | +5.68% |
|
| Current month | +11.54% | ||
| 1 month | +7.63% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
ASTRAZENECA PLC
Latest news about ASTRAZENECA PLC
More news
| Date | Price | Change |
|---|---|---|
| 24-06-14 | 17.5 | +5.68% |
| 24-06-13 | 16.56 | -2.42% |
| 24-06-12 | 16.97 | +1.50% |
| 24-06-11 | 16.72 | -6.49% |
| 24-06-10 | 17.88 | +0.73% |
Delayed Quote Börse Stuttgart
Last update June 14, 2024 at 10:31 am
More quotesStatic data
| Product type | Exotic Products |
|---|---|
| Buy / Sell | CALL |
| Underlying | ASTRAZENECA PLC |
| Issuer | Morgan Stanley |
| WKN | MA3WJX |
| ISIN | DE000MA3WJX4 |
| Date issued | 2020-11-26 |
| Strike | 9,296 p |
| Maturity | Unlimited |
| Parity | 2.19 : 1 |
| Emission price | 10 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 26.1 € |
|---|---|
| Lowest since issue | 5.07 € |
| Spread | 0.03 € |
| Spread % | 0.17% |
Company Profile
AstraZeneca PLC is one of the world's leading pharmaceutical groups. Net sales break down by source of income as follows:
- product sales (95.6%). Net sales break down by treatment area between oncology (39.2%), cardiovascular, renal and metabolic diseases (24.2%), respiratory and autoimmune diseases (13.9%), and other (22.7%; inflammatory diseases, neurological diseases, gastrointestinal and infectious diseases);
- collaboration revenue (4.4%).
Net sales are distributed geographically as follows: the United Kingdom (7.4%), Europe (21.2%), America (45.3%) and Africa-Asia-Australia (26.1%).
Sector
-
Consensus: AstraZeneca PLC
Sell
Buy
Mean consensus
BUY
Number of Analysts
23
Last Close Price
158.6
USD
Average target price
174.4
USD
Spread / Average Target
+9.95%
- Stock Market
- Certificates
- Certificat
